imiquimod has been researched along with decitabine in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Li, H; Li, X; Lin, N; Liu, L; Lu, Y; Luo, D; Sun, X; Wang, J; Yin, C; Zhang, M; Zhou, Y | 1 |
2 other study(ies) available for imiquimod and decitabine
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Aberrant promoter methylation of Wnt inhibitory factor-1 gene is a potential target for treating psoriasis.
Topics: Animals; Decitabine; Disease Models, Animal; DNA Methylation; Humans; Imiquimod; Keratinocytes; Mice; Mice, Inbred BALB C; Promoter Regions, Genetic; Psoriasis; Skin | 2023 |